|(A;A)||2||2x increased prostate cancer risk|
|(A;G)||1.5||1.5x increased prostate cancer risk|
|(G;G)||1||Normal prostate cancer risk|
rs486907 is a SNP in the RNase L RNASEL gene that has been associated with cancer risk. The basic rationale behind most of these studies is that RNase L is responsible for deactivating RNA-based viruses that are associated with certain cancers, and therefore SNPs that lead to lower RNase L activity may lead to increased cancer risk. This SNP is also known as R462Q or Arg462Gln.
This SNP was also associated with hereditary-prostate-cancer (HPC) predisposition with an odds ratio of 1.97 (p=0.07) in a study of 116 affected Finnish families.[PMID 11941539]
[PMID 20564318] Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population
[PMID 21221811] RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies
|CLNDBN||Prostate cancer, susceptibility to|
|CLNSRC||OMIM Allelic Variant UniProtKB (protein)|
[PMID 18566991] Joint effects of inflammation and androgen metabolism on prostate cancer severity.
[PMID 18575592] Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer.
[PMID 18676870] Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China.
[PMID 19379518] Development of a fingerprinting panel using medically relevant polymorphisms.
[PMID 19567509] Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.
[PMID 20565774] Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project.
[PMID 27318894] Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.